Evaluation of Plasma Non-coding RNAs as Biomarkers in Coronary Heart Disease

Prior treatment

• participate in any drug clinical trials within 3 months;

Other illness

• serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients);
• previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix);

Other

• pregnant women or plan to;
• patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years;
• patients refused to comply with the requirements of this study to complete the research work;
• according to the researchers, patients can not complete the study or not to comply with the requirements of this study (because of the reasons for the management or other reasons).

• 18 years of age or older;
• the most recent symptoms of coronary heart disease within 7 days;
• meet one of the following conditions: A. clinical history of typical ischemic chest pain (more than 5 minutes of persistent chest pain); B. serum cardiac biomarkers positive (TnT/I or creatine kinase peak greater than 99% of URL); C. Electrocardiogram changes of myocardial ischemia.